IASOinactive

IASO BIOMED, INC.

Healthcare·Endocrinology·Pre-clinical
Endocrinology

IASO BIOMED, INC. (IASO): 1 pipeline candidate · ~1 mo cash runway. Updated within the last hour.

3.9/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway0.2

0.8 months

Financial Health10.0

D/E -1.01 · 0% dilution

Pipeline Maturity2.0

Lead: Preclinical

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for IASO BIOMED, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

Cash

$3K

Quarterly Burn

$17K

Runway

0.8 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jul 2026
Today~7 mo out
Catalyst within runway

Pipeline (1 candidate)

DrugPhase
ias-167aPreclinical

Frequently asked questions

How many drug candidates are in IASO BIOMED, INC.'s pipeline?

IASO BIOMED, INC. (IASO) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is IASO BIOMED, INC.'s lead drug candidate?

IASO BIOMED, INC.'s most advanced tracked candidate is ias-167a (Preclinical) for hypogonadism.

What is IASO BIOMED, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, IASO BIOMED, INC. has approximately 0.8 months of cash runway.

Get the full picture on IASO BIOMED, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.